Editas Medicine Inc
NASDAQ:EDIT
Editas Medicine Inc
NASDAQ:EDIT
Price:
5.67 USD
0.89%
Market Closed
Updated:
May 5, 2024
P/E
Price to Earnings
Price to Earnings
-3
Current
-4.5
Median
26.8
Industry
Higher
than median
Lower
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=-3
Market Cap
/
463.6m
Net Income
-153.2m
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
|
Editas Medicine Inc
NASDAQ:EDIT
|
463.6m USD | -3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
289.2B USD | 60 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
166.7B USD | 24.8 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
104.7B USD | 26.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.4B USD | 28.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133.2B AUD | 35.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
80.7B USD | 166.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
47.8B USD | -10.1 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -57.5 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.7B USD | 27.1 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.2T KRW | 73.1 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
-2.1
2-Years Forward
P/E
-2.1
3-Years Forward
P/E
-2
You don't have any saved screeners yet
